Rousseau, C.; Baumgartner, P.; Heymann, M.-F.; Taupin, M.; Geffroy, M.; Chatal, J.-F.; Gautier, G.; Allam, N.; Gaschet, J.; Eychenne, R.;
et al. Preclinical and Clinical Feasibility Studies as the First Step Before Forthcoming Intravesical Instillation of [211At]At-anti-CA-IX Antibody (ATO-101™) Study in Patients with Non-Muscle-Invasive Bladder Cancer Unresponsive to Standard of Care. Cancers 2025, 17, 1190.
https://doi.org/10.3390/cancers17071190
AMA Style
Rousseau C, Baumgartner P, Heymann M-F, Taupin M, Geffroy M, Chatal J-F, Gautier G, Allam N, Gaschet J, Eychenne R,
et al. Preclinical and Clinical Feasibility Studies as the First Step Before Forthcoming Intravesical Instillation of [211At]At-anti-CA-IX Antibody (ATO-101™) Study in Patients with Non-Muscle-Invasive Bladder Cancer Unresponsive to Standard of Care. Cancers. 2025; 17(7):1190.
https://doi.org/10.3390/cancers17071190
Chicago/Turabian Style
Rousseau, Caroline, Pierre Baumgartner, Marie-Françoise Heymann, Manon Taupin, Maïwenn Geffroy, Jean-François Chatal, Gaëlle Gautier, Nadia Allam, Joëlle Gaschet, Romain Eychenne,
and et al. 2025. "Preclinical and Clinical Feasibility Studies as the First Step Before Forthcoming Intravesical Instillation of [211At]At-anti-CA-IX Antibody (ATO-101™) Study in Patients with Non-Muscle-Invasive Bladder Cancer Unresponsive to Standard of Care" Cancers 17, no. 7: 1190.
https://doi.org/10.3390/cancers17071190
APA Style
Rousseau, C., Baumgartner, P., Heymann, M.-F., Taupin, M., Geffroy, M., Chatal, J.-F., Gautier, G., Allam, N., Gaschet, J., Eychenne, R., Guérard, F., Gestin, J.-F., Varmenot, N., & Chérel, M.
(2025). Preclinical and Clinical Feasibility Studies as the First Step Before Forthcoming Intravesical Instillation of [211At]At-anti-CA-IX Antibody (ATO-101™) Study in Patients with Non-Muscle-Invasive Bladder Cancer Unresponsive to Standard of Care. Cancers, 17(7), 1190.
https://doi.org/10.3390/cancers17071190
